CoChat
Sign Up
Cited by 92Virus-based gene therapy researchHerpesvirus Infections and TreatmentsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.

Gene Delivery Using Herpes Simplex Virus Vectors

Burton, Edward A., Fink, David J., Glorioso, Joseph C.·2002·DNA and Cell Biology
DOI 10.1089/104454902762053864
Open this paper in CoChat — free account

Abstract

Herpes simplex virus (HSV) is a neurotropic DNA virus with many favorable properties as a gene delivery vector. HSV is highly infectious, so HSV vectors are efficient vehicles for the delivery of exogenous genetic material to cells. Viral replication is readily disrupted by null mutations in immediate early genes that in vitro can be complemented in trans, enabling straightforward production of high-titre pure preparations of non-pathogenic vector. The genome is large (152 Kb) and many of the viral genes are dispensable for replication in vitro, allowing their replacement with large or multiple transgenes. Latent infection with wild-type virus results in episomal viral persistence in sensory neuronal nuclei for the duration of the host lifetime. Transduction with replication-defective vectors causes a latent-like infection in both neural and non-neural tissue; the vectors are non-pathogenic, unable to reactivate and persist long-term. The latency active promoter complex can be exploited in vector design to achieve long-term stable transgene expression in the nervous system. HSV vectors transduce a broad range of tissues because of the wide expression pattern of the cellular receptors recognized by the virus. Increasing understanding of the processes involved in cellular entry has allowed preliminary steps to be taken towards targeting the tropism of HSV vectors. Using replication-defective HSV vectors, highly encouraging results have emerged from recent pre-clinical studies on models of neurological disease, including glioma, peripheral neuropathy, chronic pain and neurodegeneration. Consequently, HSV vectors encoding appropriate transgenes to tackle these pathogenic processes are poised to enter clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1089/104454902762053864

Cites

245 of 245 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–245 of 245

Flagged first, then by citations

Research works printed but not linked: 11

  1. ANDREANSKY S., 1997, Cancer Res., 57, 1502
  2. BOVIATSIS E.J., 1994, Gene Ther., 1, 323
  3. DILBER M.S., 1997, Cancer Res., 57, 1523
  4. 10.1089/10430349850019445 · DOI
  5. HUARD J., 1995, Gene Ther., 2, 385
  6. MORGAN C., 1968, I. Entry. J. Virol., 2, 507
  7. MORIUCHI S., 1998, Cancer Res., 58, 5731
  8. OSTENSEN M.E., 1989, J. Biol. Response Mod., 8, 53
  9. RAJCANI J., 1998, Acta Virol., 42, 103
  10. ROSENBLUM M.G., 1989, Crit. Rev. Immunol., 9, 21
  11. RUBSAM L.Z., 1999, Cancer Res., 59, 669

Cited by

Sorted by citations

See all 92

Related

See all

Metadata

Authors
Burton, E. A., Fink, D. J., & Glorioso, J. C.
Affiliations
  • University of Oxford (GB)
  • University of Pittsburgh (US)
ORCID
Venue
DNA and Cell Biology
Publisher
SAGE Publications
Published
2002-12
Volume
21
Issue
12
Pages
915-936
ISSN
  • 1044-5498 (ISSN-L)
  • 1557-7430
DOI
10.1089/104454902762053864
OpenAlex
W2173140585
Cited by
92
References
245
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 6 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 2 · 2012: 1
FWCI
1.01
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • DNA and Cell Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
herpes simplex virus vectors, gene delivery, replication-defective vectors, immediate early genes, latent infection, sensory neurons, viral tropism, neurological disease models, glioma, peripheral neuropathy, chronic pain, neurodegeneration, viral vectors
MeSH terms
Animals, Defective Viruses, Genetic Vectors, Glioma, Herpes Simplex, Humans, Nervous System, Virus Replication, Genetic Therapy, Gene Expression Regulation, Viral, Drug Delivery Systems, Central Nervous System Neoplasms, Gene Transfer Techniques, Simplexvirus, Transgenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review